The FDA submission for NVA237 (as well as the FDA submission for the combination product, QVA129) is still expected in 2014, as previously announced (#msg-74789102).
The above PR has the full dataset from the successful GLOW2 phase-3 study in which NVA237 bested placebo and had similar results to the open-label active comparator, Spiriva, in moderate-to-severe COPD. Top-line results from GLOW2 were reported in Jun 2011 (#msg-64761738).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.